Weight gain associated with the− 759C/T polymorphism of the 5HT2C receptor and olanzapine
VL Ellingrod, PJ Perry, JC Ringold… - American Journal of …, 2005 - Wiley Online Library
VL Ellingrod, PJ Perry, JC Ringold, BC Lund, K Bever‐Stille, F Fleming, TL Holman, D Miller
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005•Wiley Online LibraryBackground Weight gain from atypical antipsychotic use has become a significant problem.
Recent reports have liked the− 759 polymorphism of the 5HT2C receptor and obesity as well
as weight gain from chlorpromazine, risperidone, and clozapine. Aim To determine
associations between weight gain during olanzapine treatment and the− 759C/T
polymorphism of the 5HT2C receptor gene. Methods This study included 42 acutely ill
patients with schizophrenia (DSM‐IV). Weekly assessments included Brief Psychiatric …
Recent reports have liked the− 759 polymorphism of the 5HT2C receptor and obesity as well
as weight gain from chlorpromazine, risperidone, and clozapine. Aim To determine
associations between weight gain during olanzapine treatment and the− 759C/T
polymorphism of the 5HT2C receptor gene. Methods This study included 42 acutely ill
patients with schizophrenia (DSM‐IV). Weekly assessments included Brief Psychiatric …
Background
Weight gain from atypical antipsychotic use has become a significant problem. Recent reports have liked the −759 polymorphism of the 5HT2C receptor and obesity as well as weight gain from chlorpromazine, risperidone, and clozapine.
Aim
To determine associations between weight gain during olanzapine treatment and the −759C/T polymorphism of the 5HT2C receptor gene.
Methods
This study included 42 acutely ill patients with schizophrenia (DSM‐IV). Weekly assessments included Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Negative Symptoms (SANS), and weight measurements. Olanzapine was titrated to a fixed dose (7.5–20 mg/day) for 2–6 weeks. A 24 hr plasma level was obtained at the endpoint visit. Genomic DNA was isolated from a whole blood sample and analyzed for the −759C/T polymorphism of the 5HT2C receptor.
Results
A chi‐square analysis was conducted comparing the distribution of T and C alleles in subjects grouped as gaining more or less than 5, 7, and 10% of their baseline weight during treatment with olanzapine. A threshold of 10% was found to be significant. The distribution of T alleles was higher in subjects not gaining 10% of more of their body weight compared who did gain significant weight (11/27 (40.7%) vs. 0/15 (100%), χ2 = 11.805, P = 0.0035).
Conclusions
Subjects with a T allele of the 5HT2C receptor −759C/T polymorphism may have a lower incidence of weight gain from olanzapine over a 6 week period compared to those with the C allele. These results need to be replicated. © 2005 Wiley‐Liss, Inc.
Wiley Online Library